PD-L1 Antikörper
Kurzübersicht für PD-L1 Antikörper (ABIN6944458)
Target
Alle PD-L1 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Kreuzreaktivität
- Human
-
Aufreinigung
- Purified by Protein A.
-
Immunogen
- Recombinant human PD-L1 extracellular domain
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
-
WB 1:300-5000
FCM 1:20-100 -
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Buffer
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
-
Konservierungsmittel
- ProClin
-
Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- Store at -20°C for 12 months.
-
Haltbarkeit
- 12 months
-
-
- PD-L1 (CD274 (PD-L1))
-
Andere Bezeichnung
- PD-L1
-
Hintergrund
-
Synonyms: Programmed cell death 1 ligand 1, CD274, B7H1, PDCD1L1, PDCD1LG1, PDL1, Programmed death ligand 1
Background: Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/CD279, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443). The PDCD1/CD279-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival (PubMed:28813417, PubMed:28813410). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077).
-
Gen-ID
- 29126
-
UniProt
- Q9NZQ7
-
Pathways
- Cancer Immune Checkpoints
Target
-